PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to increase during the forecast period (2025-2034), estimates DelveInsight

DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Market Size- https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
• On 06 October 2025, Foresee Pharmaceuticals Co. Ltd conducted a clinical trial is to see if mirivadelgat will work in patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs.
• In 2024, in the US, diagnosed prevalence of PH-ILD showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females. This gender gap is expected to widen by 2034, highlighting potential differences in disease susceptibility or progression.
• In 2024, an estimated 69,000 people in the EU4 and the UK were diagnosed with PH-ILD, underscoring a substantial and growing regional disease burden.
• In France, CTD linked with PH-ILD had the highest diagnosed prevalence, with nearly 4,000 cases in 2024, while hypersensitivity pneumonitis reported the lowest burden, with just over 500 cases.
• In Japan, over 28,000 diagnosed prevalent cases of PH-ILD were reported in 2024, with the numbers projected to increase by 2034, indicating a rising disease burden.
• In 2024, IPF accounted for the largest share of PH-ILD cases in Japan at 21%, while hypersensitivity pneumonitis represented just 1%, underscoring notable variation in subtype distribution and the need for tailored diagnostic and treatment strategies.
• The leading Pulmonary Hypertension associated with Interstitial Lung Disease Companies such as Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio and others.
• Promising Pulmonary Hypertension associated with Interstitial Lung Disease Therapies such as Treprostinil liposomal, treprostinil palmitil inhalation powder, mosliciguat, H1614, Vardenafil (RT234), Seralutinib, and others.

Stay ahead in the PH-ILD Therapeutics Market with DelveInsight's Strategic Report @ PH-ILD Market Outlook- https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PH-ILD Epidemiology Segmentation in the 7MM
• Total PH-ILD Diagnosed Prevalent Cases
• PH-ILD Type-specific Diagnosed Prevalent Cases
• PH-ILD Type-specific Diagnosed Prevalent Cases
• Total PH-ILD Diagnosed Prevalent Cases
• PH-ILD Gender-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving PH-ILD epidemiology trends @ PH-ILD Prevalence- https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PH-ILD Marketed Drugs
• YUTREPIA (Treprostinil): Liquidia Corporation
YUTREPIA is a dry powder inhalation formulation of treprostinil sodium, a prostacyclin mimetic designed for the treatment of PAH. Delivered through a single-use, handheld inhaler, each capsule contains treprostinil sodium blended with carefully selected excipients L-leucine, polysorbate 80, sodium chloride, sodium citrate, and trehalose.

• TYVASO/TYVASO DPI/TREPROST (treprostinil): United Therapeutics
TYVASO and TYVASO DPI (treprostinil) are approved inhaled therapies for PAH (Group 1) and PH-ILD (Group 3), helping improve exercise capacity in adults, though effects may diminish after ~4 hours. In Japan, treprostinil is available as TREPROST, but it has been withdrawn from European markets.

PH-ILD Emerging Drugs
• Treprostinil liposomal (L606): Pharmosa Biopharm/Liquidia Corporation
L606 is a liposomal formulation of treprostinil, with liposome particle sizes ranging from 110-140 nm, suspended in a sodium citrate-bicarbonate buffer. This advanced formulation is engineered to enhance drug stability and prolong systemic circulation by protecting treprostinil from rapid degradation and clearance. The liposomal encapsulation enables a sustained pulmonary release, allowing for more consistent drug exposure over time, while minimizing peaks and troughs that may lead to side effects. The citrate-bicarbonate buffer not only helps maintain an optimal pH for lung tolerability but also supports better drug solubility and absorption.

• Treprostinil Palmitil Inhalation Powder (TPIP): Insmed
TPIP is a next-generation, once-daily dry powder formulation of a treprostinil prodrug, delivered via a convenient capsule-based inhaler. Engineered by Insmed, TPIP features a 16-carbon ester-linked modification for extended activity and is being developed for PAH, PH-ILD, and other severe pulmonary conditions. With promising Phase IIb results, a pivotal Phase III trial is expected to launch in the second half of 2025, marking a major step toward transforming treatment for rare lung diseases.

• Mosliciguat: Roivant Sciences/Pulmovant
Mosliciguat (BAY 1237592) is a first-in-class sGC activator being developed for PH-ILD, offering a nitric oxide-independent mechanism that promotes vasodilation even under hypoxic and oxidative stress conditions. It may also provide anti-inflammatory and anti-fibrotic benefits. Phase II topline results are expected in H2 2026.

Get In-Depth Knowledge on PH-ILD Market Trends and Forecasts with DelveInsight @ PH-ILD Therapeutics Market Size- https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PH-ILD Treatment Market
The PH-ILD treatment landscape is shifting from supportive care to targeted, disease-modifying approaches that address vascular remodeling, fibrosis, and inflammation. Traditional strategies, including ILD management and lung transplantation, offer limited impact on long-term outcomes, highlighting the need for more effective therapies. New drug classes with lung-targeted mechanisms are advancing PH-ILD treatment. Inhaled prostacyclins like treprostinil have enhanced exercise capacity, setting the stage for next-generation agents such as Mosliciguat (sGC activator), H1614 (HA synthesis inhibitor), and RT234 (inhaled PDE5 inhibitor). These candidates aim to deliver broader benefits-beyond vasodilation-by incorporating anti-fibrotic and anti-inflammatory effects, marking a shift toward disease-modifying approaches.

PH-ILD Market Outlook
The PH-ILD Market is undergoing significant transformation, driven by growing disease recognition, evolving clinical strategies, and novel therapeutic development. PH-ILD is the most common form of Group 3 pulmonary hypertension and represents a serious complication of ILD, contributing to cardiopulmonary disability, right heart dysfunction, and increased mortality. Despite supportive treatments such as oxygen therapy and corticosteroids to manage acute exacerbations, current standards offer limited long-term benefit and do not halt disease progression.

Scope of the PH-ILD Market Report
• Coverage- 7MM
• Forecast Period- 2025-2034
• PH-ILD Companies- Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio and others.
• PH-ILD Therapies- Treprostinil liposomal, treprostinil palmitil inhalation powder, mosliciguat, H1614, Vardenafil (RT234), Seralutinib, and others.
• PH-ILD Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• PH-ILD Unmet Needs, KOL's views, Analyst's views, PH-ILD Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive PH-ILD Market Report @ PH-ILD Market Drivers and Barriers- https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. PH-ILD Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. PH-ILD - 7MM Market Analysis
13. KOL Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.